{"gene":"CEBPA","run_date":"2026-06-09T22:57:18","timeline":{"discoveries":[{"year":1988,"finding":"C/EBP (CEBPA) was cloned and shown to encode a single protein with dual DNA-binding activities: selective binding to the CCAAT homology of viral promoters and to the enhancer core homology. The DNA-binding domain was localized to a 14-kD fragment by protease mapping, and a 60-amino-acid segment within it bears sequence similarity to myc and fos oncogenes.","method":"Recombinant bacterial expression, in vitro DNA-binding assay, protease fragment analysis, sequence analysis","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with purified recombinant protein, direct DNA-binding assay, domain mapping by proteolysis, foundational paper replicated across subsequent studies","pmids":["2850264"],"is_preprint":false},{"year":1991,"finding":"C/EBP alpha (CEBPA) protein is expressed only during the late phase of adipocyte differentiation in 3T3-L1 cells, in contrast to C/EBP beta and delta which peak early. C/EBP beta and delta form heterodimers with C/EBP alpha, and they activate transcription from the serum albumin gene promoter in hepatoma cells. This temporal expression pattern suggests a regulatory cascade controlling terminal differentiation.","method":"Western blotting, Northern blotting, transient transfection/reporter assay, heterodimerization analysis","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (Western, Northern, co-dimerization, transactivation), widely replicated across subsequent labs","pmids":["1840554"],"is_preprint":false},{"year":1991,"finding":"In the absence of specific DNA, the basic region of C/EBP bZip fragment is flexible and partially disordered; binding to a specific DNA recognition sequence induces a fully alpha-helical conformation in the basic region ('induced helical fork model'). This was demonstrated for the intact bZip protein of C/EBP.","method":"Circular dichroism (CD) spectroscopy, DNA-binding titration with symmetric and asymmetric enhancers","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct biophysical measurement of conformational change, single lab but rigorous in vitro reconstitution with intact protein and bZip fragment","pmids":["1892816"],"is_preprint":false},{"year":1995,"finding":"Homozygous deletion of c/ebp alpha in mice results in failure to store hepatic glycogen, hypoglycemia, and neonatal death. Mutant livers show 50-70% reduced glycogen synthase mRNA and delayed transcriptional induction of gluconeogenic enzymes PEPCK and glucose-6-phosphatase. Hepatocytes and adipocytes fail to accumulate lipid, and uncoupling protein expression is reduced in brown adipose tissue, establishing C/EBPα as critical for energy homeostasis.","method":"Targeted gene knockout (homozygous null mice), Northern blotting, histology","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean germline KO with specific metabolic phenotypes, replicated in subsequent conditional KO studies","pmids":["7652557"],"is_preprint":false},{"year":1996,"finding":"C/EBPα, c-Myb, and PU.1 cooperatively activate the neutrophil elastase (NE) promoter through their respective binding sites at -57, -49, and -82. Cooperative activation was observed with any combination of these factors. Either of C/EBPα's two transactivation domains cooperated with c-Myb, suggesting a coactivator protein bridges their interaction rather than direct protein-protein contact. Spatial separation of binding sites did not abolish cooperativity.","method":"Transient transfection/reporter assay (NIH 3T3, CV-1, 32D cl3 cells), gel shift/EMSA, site-directed mutagenesis of binding sites","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (reporter assay with mutagenesis, EMSA), tested in multiple cell lines, domain mapping","pmids":["8756629"],"is_preprint":false},{"year":1997,"finding":"Conditional deletion of c/ebp alpha specifically in adult mouse liver (via Cre/loxP) reduced expression of bilirubin UDP-glucuronosyltransferase, causing severe jaundice due to increased unconjugated bilirubin. Expression of PEPCK, glycogen synthase, and factor IX was strongly reduced, while transferrin, apoB, and IGF-I were unaffected, establishing C/EBPα as an essential transcriptional regulator of specific metabolic genes in adult liver.","method":"Conditional knockout (Cre/loxP recombination via adenoviral Cre delivery), Northern blotting, biochemical phenotyping","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean conditional KO with gene-specific readouts, distinct from the lethal germline KO, multiple target genes examined","pmids":["9315660"],"is_preprint":false},{"year":1998,"finding":"C/EBP alpha and C/EBP beta can induce eosinophil lineage commitment in multipotent hematopoietic progenitors (MEPs). Eosinophil differentiation can be separated into lineage commitment (transactivation-independent C/EBP function) and maturation (transactivation-dependent). Transactivation-deficient C/EBPβ alleles allowed commitment but blocked maturation.","method":"Retroviral forced expression of C/EBP isoforms in MEPs, dominant-negative allele analysis, conditional C/EBPβ activation","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — gain-of-function and dominant-negative loss-of-function with specific phenotypic readouts, domain-function dissection","pmids":["9694805"],"is_preprint":false},{"year":2001,"finding":"Retinoblastoma protein (RB) forms stable complexes with C/EBPα, C/EBPβ, and C/EBPδ. The RB small pocket domain (aa 379-792) is necessary and sufficient for interaction with C/EBP proteins. RB-C/EBP complexes directly bind C/EBP sites on DNA and activate C/EBP-dependent transcription of the surfactant protein D (SP-D) gene promoter.","method":"Co-immunoprecipitation, GST pulldown, EMSA, reporter/transient transfection assay, RB domain mutagenesis","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal binding assays and reporter assay with domain mapping, single lab","pmids":["11596110"],"is_preprint":false},{"year":2003,"finding":"C/EBPβ function is required for mitotic clonal expansion (MCE) during adipogenesis. A dominant-negative C/EBP (A-C/EBP) inhibited turnover of p27/Kip1, expression of cyclin A and CDK2, DNA replication, MCE, and subsequent adipogenesis. Mechanistically, A-C/EBP prevented nuclear import of C/EBPβ by obscuring its nuclear localization signal, blocking its normal punctate centromeric staining.","method":"Adenoviral A-C/EBP expression, immunofluorescence, BrdU/DNA replication assay, Western blotting","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 2 / Moderate — dominant-negative strategy with multiple orthogonal readouts, mechanistic localization finding linked to functional outcome","pmids":["14688407"],"is_preprint":false},{"year":2006,"finding":"FLT3-activating mutations in AML inhibit C/EBPα function via ERK1/2-mediated phosphorylation of serine 21. Pharmacological inhibition of FLT3 or MEK1 restores granulocytic differentiation. Expression of phosphorylation-resistant C/EBPα (S21A) restores differentiation, whereas the phosphomimetic S21D mutant does not, establishing ERK1/2-mediated S21 phosphorylation as a functional inactivation mechanism.","method":"Site-directed mutagenesis (S21A, S21D), stable expression in MV4;11 cells, FLT3/MEK inhibitor treatment, differentiation assay","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis of specific phosphorylation site with gain-of-function and phosphomimetic loss-of-function, mechanistic pathway defined","pmids":["16446383"],"is_preprint":false},{"year":2008,"finding":"Sumoylation of C/EBPα at lysine 159 (K159) prevents association of the SWI/SNF chromatin remodeling complex with C/EBPα, thereby hampering transactivation. K159 lies within the growth inhibitory region of C/EBPα.","method":"SUMO modification assay, Co-immunoprecipitation of SWI/SNF with C/EBPα mutants (review citing primary experimental data)","journal":"Blood cells, molecules & diseases","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — single review citing primary experimental work; mechanistic claim is well-defined (K159 sumoylation blocks SWI/SNF association) but supporting experiments cited rather than fully described in this abstract","pmids":["18406180"],"is_preprint":false},{"year":2008,"finding":"Genome-wide ChIP analysis in 3T3-L1 adipocytes showed that C/EBPα co-localizes at 3350 of 5299 PPARγ-binding sites. Most genes induced in adipogenesis are bound by both PPARγ and C/EBPα, while very few are PPARγ-specific. C/EBPα and C/EBPβ are both required with PPARγ for robust adipocyte-specific gene expression, demonstrating cooperative orchestration of adipocyte biology through adjacent binding on a genome-wide scale.","method":"Chromatin immunoprecipitation coupled with whole-genome tiling arrays (ChIP-chip), bioinformatics motif analysis","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide ChIP in physiologically relevant adipocyte model, multiple ChIP targets validated, loss-of-function for both C/EBPα and C/EBPβ","pmids":["18981473"],"is_preprint":false},{"year":2011,"finding":"PU.1 and C/EBPα synergistically create monocyte-specific enhancers that direct NF-κB p65 to distinct genome locations upon TNF-α stimulation. Co-expression of PU.1 and C/EBPα in HeLa cells conferred TNF-α responsiveness to a subset of THP-1-specific NF-κB target genes, establishing C/EBPα as a determinant of cell-type-specific enhancer formation and NF-κB targeting.","method":"Genome-wide ChIP-seq, histone modification profiling, transient expression of PU.1 and C/EBPα in HeLa cells, NF-κB reporter assays","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide location analysis combined with gain-of-function in non-myeloid cells, multiple orthogonal methods","pmids":["21402921"],"is_preprint":false},{"year":2013,"finding":"C/EBPα controls acquisition and maintenance of adult haematopoietic stem cell (HSC) quiescence. Inducible knockout of C/EBPα in adult HSCs caused pronounced increase in HSC number and enhanced proliferation, resembling fetal liver HSCs. N-Myc was identified as a direct downstream target: loss of C/EBPα caused de-repression of N-Myc, mechanistically linking C/EBPα to HSC cell-cycle control.","method":"Inducible Cre-mediated conditional knockout, transcription profiling, ChIP/target gene validation","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — inducible KO with quantitative phenotypic readouts, downstream target identified with mechanistic follow-up","pmids":["23502316"],"is_preprint":false},{"year":2016,"finding":"A single enhancer located +42 kb from CEBPA is active exclusively in myeloid cells and physically engages the CEBPA promoter. Germline deletion of this enhancer in mice specifically reduced Cebpa levels in HSCs and myeloid-primed progenitors, causing severe granulocytic differentiation defects and loss of HSC maintenance without affecting Cebpa expression in other tissues.","method":"CRISPR/Cas9 genome editing, chromosome conformation capture (3C/4C), ChIP, in vivo mouse modeling","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 / Strong — CRISPR deletion in vivo with defined enhancer-promoter looping, tissue-specific rescue experiment, multiple orthogonal methods","pmids":["26966090"],"is_preprint":false},{"year":2017,"finding":"R-2-hydroxyglutarate (R-2HG) inhibits FTO (fat mass and obesity-associated protein) activity, leading to increased global m6A RNA modification, which in turn decreases the stability of CEBPA (and MYC) transcripts, suppressing relevant pathways. This established CEBPA mRNA stability as a node regulated by the FTO/m6A axis.","method":"FTO enzymatic inhibition assay, m6A-seq, mRNA stability assay, ectopic expression, in vitro and in vivo leukemia models","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — enzymatic inhibition assay with mechanistic follow-up (m6A-seq, mRNA stability), multiple orthogonal methods, replicated in vivo","pmids":["29249359"],"is_preprint":false},{"year":2019,"finding":"Oncogenic C/EBPα p30 isoform (from N-terminal AML mutations) physically interacts with the MLL1 histone methyltransferase complex and shows global co-localization on chromatin. CRISPR/Cas9 mutagenesis of MLL1 induces proliferation arrest and myeloid differentiation in p30-expressing cells. GATA2 was identified as a direct critical transcriptional target of the p30-MLL1 interaction.","method":"Co-immunoprecipitation, ChIP-seq, CRISPR/Cas9 MLL1 mutagenesis, pharmacological MLL1 inhibition, gene expression profiling","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, genome-wide co-localization, genetic and pharmacological perturbation with specific phenotypic readouts, target gene identified","pmids":["30679799"],"is_preprint":false},{"year":2019,"finding":"Mutant CEBPA-p30 isoform activates aberrant enhancers not occupied by wild-type C/EBPα, including a leukemic enhancer upstream of Nt5e (CD73) that is physically and functionally linked to that gene. CD73 expression sustained leukemic growth via the CD73/A2AR axis, establishing a direct mechanistic link between a C/EBPα driver mutation and a druggable downstream target.","method":"Microscale in vivo ChIP-seq, chromatin conformation capture, comparative gene expression (human AML and mouse Cebpa-Lp30 model), reporter assay, pharmacological targeting","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP-seq with chromatin looping, cross-species validation, functional pharmacological rescue in vivo","pmids":["31309149"],"is_preprint":false},{"year":2020,"finding":"JAM-A promotes C/EBPα expression through suppression of β-catenin transcriptional activity and through activation of EPAC. C/EBPα then directly binds the promoter of claudin-5 to promote its transcription, enhancing endothelial barrier function. Genetic deletion of JAM-A reduced vascular permeability and claudin-5 levels; C/EBPα gain-of-function increased claudin-5 and decreased permeability; C/EBPα loss-of-function had the opposite effects.","method":"Genetic KO (JAM-A mice), ChIP on C/EBPα at claudin-5 promoter, gain/loss-of-function transfection, FITC-dextran permeability assay, pharmacological EPAC activation","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal gain/loss-of-function experiments, ChIP at target promoter, in vivo genetic model with functional permeability readout","pmids":["32673519"],"is_preprint":false},{"year":2021,"finding":"Chronic IL-1β exposure engendered potent selective expansion of Cebpa-knockout HSPCs in competitive settings. Cebpa loss did not confer cell-intrinsic competitive advantage under basal conditions. Mechanistically, C/EBPα mediates IL-1β-driven myeloid differentiation and repression of stem cell gene programs; Cebpa-KO HSPCs are resistant to the pro-differentiative effects of IL-1β, explaining their selective expansion.","method":"Competitive transplantation, inducible conditional knockout, gene expression profiling, ectopic CEBPA expression in human AML cells","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — competitive transplantation with inducible KO, mechanistic pathway delineated, human AML validation","pmids":["33914855"],"is_preprint":false},{"year":2022,"finding":"CEBPA directly interacts with the long isoform DNMT3A (but not DNMT3A2). By interacting with the DNMT3A N-terminus, CEBPA blocks DNMT3A from accessing DNA substrate and thereby inhibits its methyltransferase activity. Recurrent AML-associated CEBPA mutation N321D disrupts DNMT3A association and causes aberrant DNA hypermethylation of PRC2 target genes.","method":"Co-immunoprecipitation (CEBPA with DNMT3A isoforms), in vitro DNA methyltransferase activity assay, bisulfite sequencing/methylation profiling, site-directed mutagenesis (N321D)","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro enzymatic inhibition assay combined with Co-IP, domain-specific interaction (N-terminus), mutagenesis of AML-relevant site with methylome profiling","pmids":["35080973"],"is_preprint":false},{"year":2023,"finding":"CEBPA drives extensive chromatin compartment switching and formation of long-range chromatin hubs during B cell-to-macrophage transdifferentiation. The intrinsically disordered region (IDR) of CEBPA undergoes phase separation in vitro dependent on aromatic residues, and CEBPA forms nuclear foci in vivo in multiple cell types. This suggests phase separation through the IDR underlies CEBPA foci formation and 3D chromatin hub organization.","method":"Hi-C/chromatin conformation analysis, in vitro phase separation assay with purified CEBPA IDR, mutagenesis of aromatic residues, live-cell imaging of nuclear foci, ChIP-seq","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro phase separation with mutagenesis, supported by genome-wide chromatin architecture data and live imaging, multiple orthogonal methods in single study","pmids":["37516962"],"is_preprint":false},{"year":2024,"finding":"CEBPA restricts alveolar type 2 (AT2) cell plasticity in the mouse lung. Without CEBPA, neonatal AT2 cells reactivate the SOX9 progenitor program (mature AT2 cells cannot). Sendai virus infection bestows mature AT2 cells with neonatal plasticity in a Cebpa-mutant-dependent manner. Mechanistically, CEBPA promotes the AT2 program by recruiting the lineage TF NKX2-1.","method":"Conditional knockout (neonatal and adult), viral infection model, scRNA-seq/transcriptome profiling, ChIP/co-factor recruitment assay","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO at different developmental stages, mechanistic co-factor recruitment (NKX2-1), epigenetic maturation profiling, multiple orthogonal readouts","pmids":["38755149"],"is_preprint":false},{"year":2021,"finding":"CEBPβ preferentially binds T:G mismatches (product of 5mC deamination) with >60-fold increased affinity relative to normal C:G base pairs within a CEBP binding site. This enhanced mismatch binding inhibits repair by TDG and MBD4 in vitro, as well as repair of U:G mismatches, providing a mechanism by which CEBP site occupancy drives C-to-T somatic mutations.","method":"In vitro binding affinity assay (fluorescence anisotropy/EMSAs), in vitro DNA glycosylase repair inhibition assay, somatic mutation enrichment analysis","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — quantitative in vitro binding and enzymatic repair inhibition assays, mechanistically defined, single lab but multiple orthogonal biochemical methods","pmids":["33877329"],"is_preprint":false},{"year":2015,"finding":"The p53-KLF4-CEBPA axis is functionally connected: CEBPA gene transcription can be directly activated by p53 and KLF4. In AML patient cells, p53 inactivation correlates with reduced KLF4 and CEBPA protein levels. Restoring p53 function with chemotherapy or non-genotoxic p53 activators induces CEBPA gene expression and myeloid differentiation in AML cell lines.","method":"Reporter assay (CEBPA promoter with p53/KLF4 co-expression), protein level analysis in patient samples, pharmacological p53 restoration","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — reporter assay demonstrates direct p53/KLF4 activation of CEBPA promoter, but mechanistic depth is limited to co-transfection; patient correlation data is associative","pmids":["26408402"],"is_preprint":false}],"current_model":"CEBPA encodes a bZIP transcription factor that binds CCAAT/enhancer elements (with DNA-induced helix formation in its basic region), forms homo- and heterodimers with other C/EBP family members, and cooperates with PU.1, c-Myb, PPARγ, and RB to activate myeloid- and adipocyte-specific gene programs; its activity is regulated post-translationally by ERK1/2-mediated phosphorylation at S21 (blocking differentiation), sumoylation at K159 (blocking SWI/SNF recruitment), and interaction with DNMT3A (inhibiting de novo DNA methylation), while its IDR mediates phase separation and 3D chromatin hub formation; in hematopoiesis it maintains adult HSC quiescence by repressing N-Myc, drives granulocytic differentiation via a myeloid-specific +42 kb enhancer, and oncogenic N-terminal truncation mutations produce a p30 isoform that aberrantly co-opts the MLL1 complex to activate CD73 and GATA2 and disrupt DNMT3A interaction, causing hypermethylation and leukemogenesis."},"narrative":{"mechanistic_narrative":"CEBPA encodes a basic-region leucine-zipper (bZIP) transcription factor that binds CCAAT/enhancer DNA elements and orchestrates lineage-specific gene programs across metabolism, hematopoiesis, and epithelial differentiation [PMID:2850264, PMID:1892816]. Its DNA-binding domain adopts an 'induced helical fork' conformation, becoming fully alpha-helical only upon engaging a specific recognition sequence [PMID:1892816]. C/EBPalpha functions combinatorially: it homo- and heterodimerizes with other C/EBP family members [PMID:1840554], cooperates with c-Myb and PU.1 to build myeloid enhancers and with PU.1 to specify cell-type-restricted NF-kappaB targeting [PMID:8756629, PMID:21402921], partners with PPARgamma at thousands of shared sites to drive adipogenesis [PMID:18981473], and recruits lineage factors such as NKX2-1 to enforce alveolar type 2 identity [PMID:38755149]. In liver it is essential for energy homeostasis, controlling glycogen storage, gluconeogenic enzymes, and bilirubin conjugation [PMID:7652557, PMID:9315660]. In hematopoiesis it maintains adult HSC quiescence by repressing N-Myc and mediates IL-1beta-driven myeloid differentiation, such that its loss confers selective expansion under inflammatory stress; a myeloid-specific +42 kb enhancer that loops to the CEBPA promoter restricts this activity to the myeloid compartment [PMID:23502316, PMID:26966090, PMID:33914855]. C/EBPalpha activity is tuned post-translationally—ERK1/2 phosphorylation at serine 21 inactivates it downstream of oncogenic FLT3 and blocks granulocytic differentiation, while sumoylation at K159 blocks SWI/SNF recruitment [PMID:16446383, PMID:18406180]—and its intrinsically disordered region drives aromatic-residue-dependent phase separation that organizes long-range chromatin hubs [PMID:37516962]. C/EBPalpha also directly binds the long DNMT3A isoform and inhibits its methyltransferase activity, coupling the factor to genome methylation control [PMID:35080973]. Recurrent AML mutations corrupt these functions: the N-terminally truncated p30 isoform co-opts the MLL1 complex to activate aberrant enhancers and targets including GATA2 and CD73, while the N321D mutation disrupts the DNMT3A interaction to cause hypermethylation of PRC2 targets [PMID:30679799, PMID:31309149, PMID:35080973].","teleology":[{"year":1988,"claim":"Establishing that CEBPA encodes a single sequence-specific DNA-binding protein defined the molecular identity of the factor and localized its activity to a discrete domain.","evidence":"recombinant bacterial expression with in vitro DNA-binding and protease fragment mapping","pmids":["2850264"],"confidence":"High","gaps":["No structure of the DNA-bound complex","Cellular partners and target genes not yet defined"]},{"year":1991,"claim":"Biophysical characterization showed the basic region is disordered until DNA binding induces a fully helical fork, explaining how specific recognition is achieved.","evidence":"circular dichroism and DNA-binding titration on intact bZip protein","pmids":["1892816"],"confidence":"High","gaps":["Single biophysical method","Does not address dimer selectivity or partner-dependent binding in vivo"]},{"year":1991,"claim":"Temporal expression and heterodimerization data placed C/EBPalpha as a terminal effector in a differentiation cascade rather than an early inducer.","evidence":"Western/Northern blotting, heterodimerization and transactivation assays in adipocyte and hepatoma cells","pmids":["1840554"],"confidence":"High","gaps":["Mechanism of cascade hand-off between C/EBP family members unresolved","In vivo physiological roles not yet tested"]},{"year":1995,"claim":"Germline knockout established C/EBPalpha as essential for energy homeostasis, linking the transcription factor to specific metabolic gene programs in liver and fat.","evidence":"homozygous null mice with Northern and histological phenotyping","pmids":["7652557"],"confidence":"High","gaps":["Neonatal lethality precludes adult analysis","Direct vs indirect target genes not separated"]},{"year":1997,"claim":"Adult liver-specific conditional deletion separated developmental requirement from ongoing transcriptional control, identifying discrete target genes regulated in mature hepatocytes.","evidence":"Cre/loxP conditional KO with Northern and biochemical phenotyping","pmids":["9315660"],"confidence":"High","gaps":["Mechanism of target-gene selectivity unknown","Cofactor requirements not defined"]},{"year":1996,"claim":"Demonstrating cooperative activation with c-Myb and PU.1 revealed C/EBPalpha works combinatorially at myeloid promoters, likely via a bridging coactivator.","evidence":"reporter assays with binding-site mutagenesis and EMSA across multiple cell lines","pmids":["8756629"],"confidence":"High","gaps":["Identity of the bridging coactivator not established","Direct vs indirect cooperativity not resolved"]},{"year":1998,"claim":"Separating lineage commitment (transactivation-independent) from maturation (transactivation-dependent) showed C/EBP function is modular in hematopoietic fate decisions.","evidence":"retroviral forced expression and dominant-negative alleles in multipotent progenitors","pmids":["9694805"],"confidence":"High","gaps":["Transactivation-independent commitment mechanism undefined","Overlap with C/EBPbeta function not fully separated"]},{"year":2001,"claim":"Identifying RB as a direct binding partner that activates C/EBP-dependent transcription linked C/EBP factors to a cell-cycle regulator at target promoters.","evidence":"reciprocal Co-IP, GST pulldown, EMSA and reporter assays with RB domain mapping","pmids":["11596110"],"confidence":"Medium","gaps":["Single lab","Physiological relevance in vivo not established"]},{"year":2006,"claim":"Pinpointing ERK1/2 phosphorylation of serine 21 as a functional off-switch explained how oncogenic FLT3 signaling blocks granulocytic differentiation.","evidence":"S21A/S21D mutagenesis with stable expression and kinase-inhibitor differentiation assays in AML cells","pmids":["16446383"],"confidence":"High","gaps":["Structural consequence of S21 phosphorylation unknown","Whether phosphorylation alters DNA binding vs cofactor recruitment unresolved"]},{"year":2008,"claim":"Sumoylation at K159 was identified as a modification that blocks SWI/SNF recruitment, defining a chromatin-remodeling control point on C/EBPalpha.","evidence":"SUMO modification and Co-IP of SWI/SNF with C/EBPalpha mutants (review citing primary data)","pmids":["18406180"],"confidence":"Medium","gaps":["Primary experiments cited rather than fully described","SUMO E3 ligase and dynamics not defined"]},{"year":2008,"claim":"Genome-wide co-localization with PPARgamma established that C/EBPalpha cooperatively orchestrates the adipocyte gene program through adjacent binding.","evidence":"ChIP-chip in 3T3-L1 adipocytes with motif analysis and loss-of-function","pmids":["18981473"],"confidence":"High","gaps":["Order of recruitment between PPARgamma and C/EBPalpha not resolved","Direct physical interaction at shared sites not shown"]},{"year":2011,"claim":"PU.1/C/EBPalpha synergy in creating monocyte-specific enhancers showed C/EBPalpha determines cell-type-specific NF-kappaB genomic targeting.","evidence":"ChIP-seq, histone profiling and ectopic PU.1/C/EBPalpha expression in non-myeloid cells","pmids":["21402921"],"confidence":"High","gaps":["Mechanism of de novo enhancer establishment not detailed","Direct C/EBPalpha-PU.1 contact not demonstrated"]},{"year":2013,"claim":"Inducible HSC knockout identified C/EBPalpha as a controller of adult HSC quiescence acting through direct repression of N-Myc.","evidence":"inducible conditional KO with transcriptional profiling and ChIP target validation","pmids":["23502316"],"confidence":"High","gaps":["How C/EBPalpha represses N-Myc mechanistically not defined","Cofactors of repression unknown"]},{"year":2015,"claim":"Positioning CEBPA downstream of a p53-KLF4 axis provided a transcriptional input controlling its expression and a route to restore differentiation in AML.","evidence":"CEBPA-promoter reporter assays with p53/KLF4, patient-sample correlation, pharmacological p53 restoration","pmids":["26408402"],"confidence":"Medium","gaps":["Promoter activation shown only by co-transfection","Patient correlation is associative"]},{"year":2016,"claim":"A myeloid-specific +42 kb enhancer that loops to the promoter was shown to confer tissue-restricted CEBPA expression essential for granulopoiesis and HSC maintenance.","evidence":"in vivo CRISPR enhancer deletion with 3C/4C, ChIP and phenotyping","pmids":["26966090"],"confidence":"High","gaps":["Trans-factors binding the enhancer not fully cataloged","Mechanism of looping not defined"]},{"year":2017,"claim":"Identifying CEBPA mRNA as a target of the FTO/m6A axis revealed post-transcriptional control of its abundance in leukemia.","evidence":"FTO inhibition assay, m6A-seq, mRNA stability assays in leukemia models","pmids":["29249359"],"confidence":"High","gaps":["m6A reader mediating CEBPA decay not identified here","Site-specific m6A marks on CEBPA not mapped"]},{"year":2019,"claim":"The oncogenic p30 isoform was shown to physically co-opt the MLL1 complex to activate aberrant targets such as GATA2, defining a gain-of-function leukemogenic mechanism.","evidence":"reciprocal Co-IP, ChIP-seq, CRISPR and pharmacological MLL1 perturbation","pmids":["30679799"],"confidence":"High","gaps":["Structural basis of p30-MLL1 interaction unknown","Why full-length C/EBPalpha does not recruit MLL1 not resolved"]},{"year":2019,"claim":"Mapping p30-specific aberrant enhancers to CD73 connected a CEBPA driver mutation to a druggable downstream adenosine axis.","evidence":"in vivo ChIP-seq, chromatin conformation capture, cross-species expression and pharmacological targeting","pmids":["31309149"],"confidence":"High","gaps":["Determinants of p30 enhancer selectivity not defined","Generality across CEBPA-mutant AML subtypes unclear"]},{"year":2021,"claim":"Competitive transplantation revealed C/EBPalpha as the effector of IL-1beta-driven myeloid differentiation, explaining selective expansion of Cebpa-mutant clones under chronic inflammation.","evidence":"inducible conditional KO with competitive transplantation, profiling and human AML validation","pmids":["33914855"],"confidence":"High","gaps":["Direct IL-1beta-to-CEBPA signaling intermediates not mapped","Whether effect is shared with other inflammatory cytokines untested"]},{"year":2021,"claim":"Demonstrating high-affinity binding of CEBP sites to T:G mismatches that blocks glycosylase repair provided a mechanism linking factor occupancy to somatic C-to-T mutation.","evidence":"in vitro binding affinity and glycosylase repair-inhibition assays with somatic mutation enrichment analysis","pmids":["33877329"],"confidence":"High","gaps":["Shown for CEBPbeta; CEBPA-specific contribution not isolated","In vivo mutagenesis at CEBPA-bound sites not demonstrated"]},{"year":2020,"claim":"Placing C/EBPalpha downstream of JAM-A signaling and upstream of claudin-5 transcription extended its role to endothelial barrier function.","evidence":"JAM-A KO mice, ChIP at claudin-5 promoter, reciprocal gain/loss-of-function and permeability assays","pmids":["32673519"],"confidence":"High","gaps":["How JAM-A/EPAC signaling reaches CEBPA not detailed","Cofactors at the claudin-5 promoter unknown"]},{"year":2022,"claim":"Direct inhibition of DNMT3A methyltransferase activity by CEBPA, disrupted by the AML N321D mutation, established CEBPA as a guardian against aberrant DNA methylation.","evidence":"Co-IP with DNMT3A isoforms, in vitro methyltransferase assay, bisulfite profiling and N321D mutagenesis","pmids":["35080973"],"confidence":"High","gaps":["Structural basis of CEBPA-DNMT3A N-terminus contact unknown","Genomic targeting of the inhibitory effect not fully resolved"]},{"year":2023,"claim":"Showing that the CEBPA IDR phase-separates and organizes long-range chromatin hubs added a biophysical layer to how the factor reshapes 3D genome architecture.","evidence":"in vitro phase separation with aromatic-residue mutagenesis, Hi-C, live imaging and ChIP-seq during transdifferentiation","pmids":["37516962"],"confidence":"High","gaps":["Functional requirement of phase separation for target activation not isolated","Whether condensates form at endogenous physiological concentrations unresolved"]},{"year":2024,"claim":"Conditional deletion in lung showed CEBPA restricts alveolar type 2 cell plasticity by recruiting NKX2-1 and suppressing a SOX9 progenitor program.","evidence":"neonatal and adult conditional KO, viral infection model, scRNA-seq and cofactor recruitment assays","pmids":["38755149"],"confidence":"High","gaps":["Mechanism of NKX2-1 recruitment not detailed","How injury overrides CEBPA restriction unresolved"]},{"year":null,"claim":"How the combinatorial logic—dimer partner choice, IDR-driven condensates, post-translational marks, and DNMT3A control—is integrated to select context-specific target genes remains unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No unified structural model of partner-dependent target selection","Relationship between phase separation and post-translational modification states untested","Quantitative link between condensate formation and transcriptional output missing"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,1,4,11,13,18]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,2,23]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[20]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[8,21]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[21]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,1,4,11]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[6,13,14,22]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[3,5,11]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[16,17,20]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[10,16,21]}],"complexes":[],"partners":["PU.1","C-MYB","PPARG","RB1","MLL1","DNMT3A","NKX2-1","CEBPB"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P49715","full_name":"CCAAT/enhancer-binding protein alpha","aliases":[],"length_aa":358,"mass_kda":37.6,"function":"Transcription factor that coordinates proliferation arrest and the differentiation of myeloid progenitors, adipocytes, hepatocytes, and cells of the lung and the placenta. Binds directly to the consensus DNA sequence 5'-T[TG]NNGNAA[TG]-3' acting as an activator on distinct target genes (PubMed:11242107). During early embryogenesis, plays essential and redundant functions with CEBPB. Essential for the transition from common myeloid progenitors (CMP) to granulocyte/monocyte progenitors (GMP). Critical for the proper development of the liver and the lung (By similarity). Necessary for terminal adipocyte differentiation, is required for postnatal maintenance of systemic energy homeostasis and lipid storage (By similarity). To regulate these different processes at the proper moment and tissue, interplays with other transcription factors and modulators. Down-regulates the expression of genes that maintain cells in an undifferentiated and proliferative state through E2F1 repression, which is critical for its ability to induce adipocyte and granulocyte terminal differentiation. Reciprocally E2F1 blocks adipocyte differentiation by binding to specific promoters and repressing CEBPA binding to its target gene promoters. Proliferation arrest also depends on a functional binding to SWI/SNF complex (PubMed:14660596). In liver, regulates gluconeogenesis and lipogenesis through different mechanisms. To regulate gluconeogenesis, functionally cooperates with FOXO1 binding to IRE-controlled promoters and regulating the expression of target genes such as PCK1 or G6PC1. To modulate lipogenesis, interacts and transcriptionally synergizes with SREBF1 in promoter activation of specific lipogenic target genes such as ACAS2. In adipose tissue, seems to act as FOXO1 coactivator accessing to ADIPOQ promoter through FOXO1 binding sites (By similarity) Can act as dominant-negative. Binds DNA and have transctivation activity, even if much less efficiently than isoform 2. Does not inhibit cell proliferation (PubMed:14660596) Directly and specifically enhances ribosomal DNA transcription interacting with RNA polymerase I-specific cofactors and inducing histone acetylation","subcellular_location":"Nucleus, nucleolus","url":"https://www.uniprot.org/uniprotkb/P49715/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CEBPA","classification":"Not Classified","n_dependent_lines":56,"n_total_lines":1208,"dependency_fraction":0.046357615894039736},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CEBPA","total_profiled":1310},"omim":[{"mim_id":"621163","title":"ADIPOGENESIS REGULATORY FACTOR; ADIRF","url":"https://www.omim.org/entry/621163"},{"mim_id":"620560","title":"CEBPA DIVERGENT TRANSCRIPT; CEBPA-DT","url":"https://www.omim.org/entry/620560"},{"mim_id":"619640","title":"LYSINE DEMETHYLASE 7A; KDM7A","url":"https://www.omim.org/entry/619640"},{"mim_id":"619246","title":"SPEXIN HORMONE; SPX","url":"https://www.omim.org/entry/619246"},{"mim_id":"618819","title":"PBX HOMEOBOX-INTERACTING PROTEIN 1; PBXIP1","url":"https://www.omim.org/entry/618819"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Vesicles","reliability":"Additional"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"adipose tissue","ntpm":92.7},{"tissue":"breast","ntpm":67.7},{"tissue":"liver","ntpm":198.2},{"tissue":"skin 1","ntpm":115.0}],"url":"https://www.proteinatlas.org/search/CEBPA"},"hgnc":{"alias_symbol":["C/EBP-alpha"],"prev_symbol":["CEBP"]},"alphafold":{"accession":"P49715","domains":[{"cath_id":"1.20.5","chopping":"288-358","consensus_level":"medium","plddt":92.2892,"start":288,"end":358}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P49715","model_url":"https://alphafold.ebi.ac.uk/files/AF-P49715-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P49715-F1-predicted_aligned_error_v6.png","plddt_mean":61.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CEBPA","jax_strain_url":"https://www.jax.org/strain/search?query=CEBPA"},"sequence":{"accession":"P49715","fasta_url":"https://rest.uniprot.org/uniprotkb/P49715.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P49715/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P49715"}},"corpus_meta":[{"pmid":"1840554","id":"PMC_1840554","title":"Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells.","date":"1991","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/1840554","citation_count":1514,"is_preprint":false},{"pmid":"2850264","id":"PMC_2850264","title":"Isolation of a recombinant copy of the gene encoding C/EBP.","date":"1988","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/2850264","citation_count":927,"is_preprint":false},{"pmid":"29249359","id":"PMC_29249359","title":"R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling.","date":"2017","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/29249359","citation_count":917,"is_preprint":false},{"pmid":"7652557","id":"PMC_7652557","title":"Impaired energy homeostasis in C/EBP alpha knockout mice.","date":"1995","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/7652557","citation_count":816,"is_preprint":false},{"pmid":"18981473","id":"PMC_18981473","title":"PPARgamma and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale.","date":"2008","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/18981473","citation_count":693,"is_preprint":false},{"pmid":"10619021","id":"PMC_10619021","title":"A C/EBP beta isoform recruits the SWI/SNF complex to activate myeloid genes.","date":"1999","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/10619021","citation_count":276,"is_preprint":false},{"pmid":"15944395","id":"PMC_15944395","title":"Molecular stop signs: regulation of cell-cycle arrest by C/EBP transcription factors.","date":"2005","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/15944395","citation_count":237,"is_preprint":false},{"pmid":"8530141","id":"PMC_8530141","title":"The C/EBP family of transcription factors.","date":"1995","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/8530141","citation_count":221,"is_preprint":false},{"pmid":"8756629","id":"PMC_8756629","title":"C/EBP, c-Myb, and PU.1 cooperate to regulate the neutrophil elastase promoter.","date":"1996","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8756629","citation_count":209,"is_preprint":false},{"pmid":"23665916","id":"PMC_23665916","title":"C/EBP maintains chromatin accessibility in liver and facilitates glucocorticoid receptor recruitment to steroid response elements.","date":"2013","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/23665916","citation_count":190,"is_preprint":false},{"pmid":"23160954","id":"PMC_23160954","title":"C/EBP transcription factors mediate epicardial activation during heart development and injury.","date":"2012","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/23160954","citation_count":188,"is_preprint":false},{"pmid":"16446383","id":"PMC_16446383","title":"Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations.","date":"2006","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16446383","citation_count":172,"is_preprint":false},{"pmid":"7929820","id":"PMC_7929820","title":"C/EBP beta regulation of the tumor necrosis factor alpha gene.","date":"1994","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/7929820","citation_count":161,"is_preprint":false},{"pmid":"9315660","id":"PMC_9315660","title":"Disruption of the c/ebp alpha gene in adult mouse liver.","date":"1997","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9315660","citation_count":161,"is_preprint":false},{"pmid":"14688407","id":"PMC_14688407","title":"Dominant-negative C/EBP disrupts mitotic clonal expansion and differentiation of 3T3-L1 preadipocytes.","date":"2003","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/14688407","citation_count":157,"is_preprint":false},{"pmid":"11353682","id":"PMC_11353682","title":"Altered expression of C/EBP family members results in decreased adipogenesis with aging.","date":"2001","source":"American journal of physiology. Regulatory, integrative and comparative physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11353682","citation_count":146,"is_preprint":false},{"pmid":"15674366","id":"PMC_15674366","title":"CEBPA point mutations in hematological malignancies.","date":"2005","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/15674366","citation_count":140,"is_preprint":false},{"pmid":"15985538","id":"PMC_15985538","title":"Transcription profiling of C/EBP targets identifies Per2 as a gene implicated in myeloid leukemia.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15985538","citation_count":127,"is_preprint":false},{"pmid":"9506442","id":"PMC_9506442","title":"Transcription factors C/EBP alpha, C/EBP beta, and CHOP (Gadd153) expressed during the differentiation program of keratinocytes in vitro and in vivo.","date":"1998","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/9506442","citation_count":123,"is_preprint":false},{"pmid":"29464001","id":"PMC_29464001","title":"PIWIL3/OIP5-AS1/miR-367-3p/CEBPA feedback loop regulates the biological behavior of glioma cells.","date":"2018","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/29464001","citation_count":121,"is_preprint":false},{"pmid":"23502316","id":"PMC_23502316","title":"C/EBPa controls acquisition and maintenance of adult haematopoietic stem cell quiescence.","date":"2013","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/23502316","citation_count":120,"is_preprint":false},{"pmid":"34320176","id":"PMC_34320176","title":"CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome.","date":"2022","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/34320176","citation_count":117,"is_preprint":false},{"pmid":"1892816","id":"PMC_1892816","title":"DNA-induced increase in the alpha-helical content of C/EBP and GCN4.","date":"1991","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1892816","citation_count":114,"is_preprint":false},{"pmid":"8664543","id":"PMC_8664543","title":"C/EBP alpha: a critical regulator of genes governing integrative metabolic processes.","date":"1995","source":"Current opinion in genetics & development","url":"https://pubmed.ncbi.nlm.nih.gov/8664543","citation_count":109,"is_preprint":false},{"pmid":"32673519","id":"PMC_32673519","title":"JAM-A Acts via C/EBP-α to Promote Claudin-5 Expression and Enhance Endothelial Barrier Function.","date":"2020","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/32673519","citation_count":106,"is_preprint":false},{"pmid":"10319019","id":"PMC_10319019","title":"The C/EBP family of transcription factors in the liver and other organs.","date":"1998","source":"International journal of experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/10319019","citation_count":104,"is_preprint":false},{"pmid":"9694805","id":"PMC_9694805","title":"Distinct C/EBP functions are required for eosinophil lineage commitment and maturation.","date":"1998","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/9694805","citation_count":92,"is_preprint":false},{"pmid":"19706798","id":"PMC_19706798","title":"Complexity of CEBPA dysregulation in human acute myeloid leukemia.","date":"2009","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/19706798","citation_count":91,"is_preprint":false},{"pmid":"12959923","id":"PMC_12959923","title":"C/EBP transcription factors in the lung epithelium.","date":"2003","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12959923","citation_count":83,"is_preprint":false},{"pmid":"23720735","id":"PMC_23720735","title":"C/EBP homologous protein-induced macrophage apoptosis protects mice from steatohepatitis.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23720735","citation_count":76,"is_preprint":false},{"pmid":"11792653","id":"PMC_11792653","title":"C/EBP DNA-binding activity is upregulated by a glucocorticoid-dependent mechanism in septic muscle.","date":"2002","source":"American journal of physiology. Regulatory, integrative and comparative physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11792653","citation_count":74,"is_preprint":false},{"pmid":"32430494","id":"PMC_32430494","title":"Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA).","date":"2020","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/32430494","citation_count":74,"is_preprint":false},{"pmid":"26966090","id":"PMC_26966090","title":"An autonomous CEBPA enhancer specific for myeloid-lineage priming and neutrophilic differentiation.","date":"2016","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/26966090","citation_count":73,"is_preprint":false},{"pmid":"21402921","id":"PMC_21402921","title":"PU.1 and C/EBP(alpha) synergistically program distinct response to NF-kappaB activation through establishing monocyte specific enhancers.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/21402921","citation_count":67,"is_preprint":false},{"pmid":"24351550","id":"PMC_24351550","title":"C/EBP homologous protein drives pro-catabolic responses in chondrocytes.","date":"2013","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/24351550","citation_count":62,"is_preprint":false},{"pmid":"10845904","id":"PMC_10845904","title":"Sp1 and C/EBP are necessary to activate the lactoferrin gene promoter during myeloid differentiation.","date":"2000","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/10845904","citation_count":60,"is_preprint":false},{"pmid":"29695233","id":"PMC_29695233","title":"Apigetrin inhibits adipogenesis in 3T3-L1 cells by downregulating PPARγ and CEBP-α.","date":"2018","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/29695233","citation_count":59,"is_preprint":false},{"pmid":"16400006","id":"PMC_16400006","title":"Expression and function of C/EBP homology protein (GADD153) in podocytes.","date":"2006","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/16400006","citation_count":55,"is_preprint":false},{"pmid":"33323974","id":"PMC_33323974","title":"STAT3 promotes melanoma metastasis by CEBP-induced repression of the MITF pathway.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/33323974","citation_count":52,"is_preprint":false},{"pmid":"33914855","id":"PMC_33914855","title":"Chronic interleukin-1 exposure triggers selection for Cebpa-knockout multipotent hematopoietic progenitors.","date":"2021","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33914855","citation_count":52,"is_preprint":false},{"pmid":"12821655","id":"PMC_12821655","title":"Subnuclear localization of C/EBP beta is regulated by growth hormone and dependent on MAPK.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12821655","citation_count":52,"is_preprint":false},{"pmid":"11750126","id":"PMC_11750126","title":"Molecular cloning, genetic mapping, and expression analysis of four zebrafish c/ebp genes.","date":"2001","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/11750126","citation_count":50,"is_preprint":false},{"pmid":"28637622","id":"PMC_28637622","title":"Familial CEBPA-mutated acute myeloid leukemia.","date":"2017","source":"Seminars in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/28637622","citation_count":49,"is_preprint":false},{"pmid":"28273455","id":"PMC_28273455","title":"A Bach2-Cebp Gene Regulatory Network for the Commitment of Multipotent Hematopoietic Progenitors.","date":"2017","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/28273455","citation_count":49,"is_preprint":false},{"pmid":"8680485","id":"PMC_8680485","title":"Control of adipocyte differentiation by CCAAT/enhancer binding protein alpha (C/EBP alpha).","date":"1996","source":"International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity","url":"https://pubmed.ncbi.nlm.nih.gov/8680485","citation_count":47,"is_preprint":false},{"pmid":"9796920","id":"PMC_9796920","title":"STAT6, NF-kappaB and C/EBP in CD23 expression and IgE production.","date":"1998","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9796920","citation_count":47,"is_preprint":false},{"pmid":"36471363","id":"PMC_36471363","title":"LncRNA CEBPA-DT promotes liver cancer metastasis through DDR2/β-catenin activation via interacting with hnRNPC.","date":"2022","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/36471363","citation_count":45,"is_preprint":false},{"pmid":"26408402","id":"PMC_26408402","title":"Inactivation of the p53-KLF4-CEBPA Axis in Acute Myeloid Leukemia.","date":"2015","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/26408402","citation_count":43,"is_preprint":false},{"pmid":"22776069","id":"PMC_22776069","title":"Inhibition of CD200R1 expression by C/EBP β in reactive microglial cells.","date":"2012","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/22776069","citation_count":42,"is_preprint":false},{"pmid":"11596110","id":"PMC_11596110","title":"Retinoblastoma protein complexes with C/EBP proteins and activates C/EBP-mediated transcription.","date":"2001","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11596110","citation_count":41,"is_preprint":false},{"pmid":"31309149","id":"PMC_31309149","title":"Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML.","date":"2019","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/31309149","citation_count":40,"is_preprint":false},{"pmid":"25886310","id":"PMC_25886310","title":"DNA methyltransferase 1 functions through C/ebpa to maintain hematopoietic stem and progenitor cells in zebrafish.","date":"2015","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25886310","citation_count":40,"is_preprint":false},{"pmid":"31100494","id":"PMC_31100494","title":"Estradiol stimulates adipogenesis and Slc2a4/GLUT4 expression via ESR1-mediated activation of CEBPA.","date":"2019","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/31100494","citation_count":39,"is_preprint":false},{"pmid":"29886828","id":"PMC_29886828","title":"Development of MTL-CEBPA: Small Activating RNA Drug for Hepatocellular Carcinoma.","date":"2018","source":"Current pharmaceutical biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/29886828","citation_count":38,"is_preprint":false},{"pmid":"12970736","id":"PMC_12970736","title":"Regulation of Bcl-2 expression by C/EBP in t(14;18) lymphoma cells.","date":"2003","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12970736","citation_count":37,"is_preprint":false},{"pmid":"23881867","id":"PMC_23881867","title":"Reciprocal modulation of C/EBP-α and C/EBP-β by IL-13 in activated microglia prevents neuronal death.","date":"2013","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23881867","citation_count":36,"is_preprint":false},{"pmid":"31909714","id":"PMC_31909714","title":"Roles of C/EBP class bZip proteins in the growth and cell competition of Rp ('Minute') mutants in Drosophila.","date":"2020","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/31909714","citation_count":36,"is_preprint":false},{"pmid":"23646198","id":"PMC_23646198","title":"Ablation of C/EBP homologous protein does not protect T17M RHO mice from retinal degeneration.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23646198","citation_count":35,"is_preprint":false},{"pmid":"26025484","id":"PMC_26025484","title":"CEBPA methylation and mutation in myelodysplastic syndrome.","date":"2015","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/26025484","citation_count":34,"is_preprint":false},{"pmid":"35178345","id":"PMC_35178345","title":"Acute Myeloid Leukemia With CEBPA Mutations: Current Progress and Future Directions.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35178345","citation_count":34,"is_preprint":false},{"pmid":"32086816","id":"PMC_32086816","title":"CCAAT enhancer binding protein alpha (CEBPA) biallelic acute myeloid leukaemia: cooperating lesions, molecular mechanisms and clinical relevance.","date":"2020","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/32086816","citation_count":34,"is_preprint":false},{"pmid":"15519652","id":"PMC_15519652","title":"Suppression of C/EBP alpha expression in biliary cell differentiation from hepatoblasts during mouse liver development.","date":"2004","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/15519652","citation_count":34,"is_preprint":false},{"pmid":"18166146","id":"PMC_18166146","title":"C/EBP homologous protein is crucial for the acceleration of experimental pancreatitis.","date":"2007","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18166146","citation_count":33,"is_preprint":false},{"pmid":"16220546","id":"PMC_16220546","title":"C/EBP homologous protein is necessary for normal osteoblastic function.","date":"2006","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16220546","citation_count":33,"is_preprint":false},{"pmid":"30852139","id":"PMC_30852139","title":"Anti-inflammatory Activity of MTL-CEBPA, a Small Activating RNA Drug, in LPS-Stimulated Monocytes and Humanized Mice.","date":"2019","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30852139","citation_count":33,"is_preprint":false},{"pmid":"1525039","id":"PMC_1525039","title":"Characterization and developmental expression of Xenopus C/EBP gene.","date":"1992","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/1525039","citation_count":32,"is_preprint":false},{"pmid":"20829351","id":"PMC_20829351","title":"C/EBP{delta} and STAT-1 are required for TLR8 transcriptional activity.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20829351","citation_count":31,"is_preprint":false},{"pmid":"25314137","id":"PMC_25314137","title":"Mmu-miR-615-3p regulates lipoapoptosis by inhibiting C/EBP homologous protein.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25314137","citation_count":31,"is_preprint":false},{"pmid":"35080973","id":"PMC_35080973","title":"Tumor suppressor CEBPA interacts with and inhibits DNMT3A activity.","date":"2022","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/35080973","citation_count":30,"is_preprint":false},{"pmid":"24584857","id":"PMC_24584857","title":"CEBPA-dependent HK3 and KLF5 expression in primary AML and during AML differentiation.","date":"2014","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/24584857","citation_count":29,"is_preprint":false},{"pmid":"19465518","id":"PMC_19465518","title":"C/EBP{alpha} is required for pulmonary cytoprotection during hyperoxia.","date":"2009","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/19465518","citation_count":29,"is_preprint":false},{"pmid":"23990620","id":"PMC_23990620","title":"Ikaros limits basophil development by suppressing C/EBP-α expression.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23990620","citation_count":29,"is_preprint":false},{"pmid":"22396222","id":"PMC_22396222","title":"Artemisinic acid is a regulator of adipocyte differentiation and C/EBP δ expression.","date":"2012","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22396222","citation_count":29,"is_preprint":false},{"pmid":"38755149","id":"PMC_38755149","title":"CEBPA restricts alveolar type 2 cell plasticity during development and injury-repair.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38755149","citation_count":28,"is_preprint":false},{"pmid":"30679799","id":"PMC_30679799","title":"CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex.","date":"2019","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/30679799","citation_count":27,"is_preprint":false},{"pmid":"29884649","id":"PMC_29884649","title":"Impaired DNA demethylation of C/EBP sites causes premature aging.","date":"2018","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/29884649","citation_count":26,"is_preprint":false},{"pmid":"34807506","id":"PMC_34807506","title":"METTL3/14 and IL-17 signaling contribute to CEBPA-DT enhanced oral cancer cisplatin resistance.","date":"2021","source":"Oral diseases","url":"https://pubmed.ncbi.nlm.nih.gov/34807506","citation_count":26,"is_preprint":false},{"pmid":"32160715","id":"PMC_32160715","title":"lncRNA CEBPA-AS1 Overexpression Inhibits Proliferation and Migration and Stimulates Apoptosis of OS Cells via Notch Signaling.","date":"2019","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/32160715","citation_count":26,"is_preprint":false},{"pmid":"30348891","id":"PMC_30348891","title":"Foxp3 expression in induced regulatory T cells is stabilized by C/EBP in inflammatory environments.","date":"2018","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/30348891","citation_count":25,"is_preprint":false},{"pmid":"31867767","id":"PMC_31867767","title":"Gain-of-Function Effects of N-Terminal CEBPA Mutations in Acute Myeloid Leukemia.","date":"2019","source":"BioEssays : news and reviews in molecular, cellular and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/31867767","citation_count":24,"is_preprint":false},{"pmid":"18406180","id":"PMC_18406180","title":"Sumoylation and the function of CCAAT enhancer binding protein alpha (C/EBP alpha).","date":"2008","source":"Blood cells, molecules & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/18406180","citation_count":24,"is_preprint":false},{"pmid":"31075711","id":"PMC_31075711","title":"Shikonin induces apoptosis and suppresses growth in keratinocytes via CEBP-δ upregulation.","date":"2019","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31075711","citation_count":24,"is_preprint":false},{"pmid":"33831168","id":"PMC_33831168","title":"Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double-mutant AML.","date":"2021","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/33831168","citation_count":24,"is_preprint":false},{"pmid":"37516962","id":"PMC_37516962","title":"CEBPA phase separation links transcriptional activity and 3D chromatin hubs.","date":"2023","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/37516962","citation_count":23,"is_preprint":false},{"pmid":"27644413","id":"PMC_27644413","title":"Role of C/EBP-α in Adriamycin-induced podocyte injury.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27644413","citation_count":23,"is_preprint":false},{"pmid":"11012671","id":"PMC_11012671","title":"Regulation of Gadd45gamma expression by C/EBP.","date":"2000","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11012671","citation_count":23,"is_preprint":false},{"pmid":"31477806","id":"PMC_31477806","title":"Companion gene mutations and their clinical significance in AML with double mutant CEBPA.","date":"2019","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31477806","citation_count":23,"is_preprint":false},{"pmid":"20386538","id":"PMC_20386538","title":"C/EBP alpha expression is associated with homeostasis of the gastric epithelium and with gastric carcinogenesis.","date":"2010","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/20386538","citation_count":23,"is_preprint":false},{"pmid":"9717674","id":"PMC_9717674","title":"The transcription factors c-myb and C/EBP alpha regulate the monocytic/myeloic gene MRP14.","date":"1998","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/9717674","citation_count":22,"is_preprint":false},{"pmid":"31829168","id":"PMC_31829168","title":"Targeted regulation of fibroblast state by CRISPR-mediated CEBPA expression.","date":"2019","source":"Respiratory research","url":"https://pubmed.ncbi.nlm.nih.gov/31829168","citation_count":21,"is_preprint":false},{"pmid":"23541085","id":"PMC_23541085","title":"Methylation status of CEBPA gene promoter in chronic myeloid leukemia.","date":"2013","source":"Hematology (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/23541085","citation_count":21,"is_preprint":false},{"pmid":"18957690","id":"PMC_18957690","title":"The HIF-1 alpha-C/EBP alpha axis.","date":"2008","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/18957690","citation_count":20,"is_preprint":false},{"pmid":"19932685","id":"PMC_19932685","title":"Albumin mediates PPAR-gamma or C/EBP-alpha-induced phenotypic changes in pancreatic stellate cells.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19932685","citation_count":20,"is_preprint":false},{"pmid":"27496643","id":"PMC_27496643","title":"Crosstalk between C/EBP homologous protein (CHOP) and glucocorticoid receptor in lung cancer.","date":"2016","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/27496643","citation_count":19,"is_preprint":false},{"pmid":"34502076","id":"PMC_34502076","title":"MTL-CEBPA Combined with Immunotherapy or RFA Enhances Immunological Anti-Tumor Response in Preclinical Models.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34502076","citation_count":19,"is_preprint":false},{"pmid":"39375377","id":"PMC_39375377","title":"TRβ activation confers AT2-to-AT1 cell differentiation and anti-fibrosis during lung repair via KLF2 and CEBPA.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39375377","citation_count":18,"is_preprint":false},{"pmid":"22715349","id":"PMC_22715349","title":"Asthma and COPD - The C/EBP Connection.","date":"2012","source":"The open respiratory medicine journal","url":"https://pubmed.ncbi.nlm.nih.gov/22715349","citation_count":18,"is_preprint":false},{"pmid":"33877329","id":"PMC_33877329","title":"Preferential CEBP binding to T:G mismatches and increased C-to-T human somatic mutations.","date":"2021","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/33877329","citation_count":17,"is_preprint":false},{"pmid":"18308386","id":"PMC_18308386","title":"PU.1 and CEBPA expression in acute myeloid leukemia.","date":"2008","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/18308386","citation_count":16,"is_preprint":false},{"pmid":"39267787","id":"PMC_39267787","title":"Oncofetal TRIM71 drives liver cancer carcinogenesis through remodeling CEBPA-mediated serine/glycine metabolism.","date":"2024","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/39267787","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47486,"output_tokens":6829,"usd":0.122446,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16032,"output_tokens":6358,"usd":0.119555,"stage2_stop_reason":"end_turn"},"total_usd":0.242001,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1988,\n      \"finding\": \"C/EBP (CEBPA) was cloned and shown to encode a single protein with dual DNA-binding activities: selective binding to the CCAAT homology of viral promoters and to the enhancer core homology. The DNA-binding domain was localized to a 14-kD fragment by protease mapping, and a 60-amino-acid segment within it bears sequence similarity to myc and fos oncogenes.\",\n      \"method\": \"Recombinant bacterial expression, in vitro DNA-binding assay, protease fragment analysis, sequence analysis\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with purified recombinant protein, direct DNA-binding assay, domain mapping by proteolysis, foundational paper replicated across subsequent studies\",\n      \"pmids\": [\"2850264\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"C/EBP alpha (CEBPA) protein is expressed only during the late phase of adipocyte differentiation in 3T3-L1 cells, in contrast to C/EBP beta and delta which peak early. C/EBP beta and delta form heterodimers with C/EBP alpha, and they activate transcription from the serum albumin gene promoter in hepatoma cells. This temporal expression pattern suggests a regulatory cascade controlling terminal differentiation.\",\n      \"method\": \"Western blotting, Northern blotting, transient transfection/reporter assay, heterodimerization analysis\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (Western, Northern, co-dimerization, transactivation), widely replicated across subsequent labs\",\n      \"pmids\": [\"1840554\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"In the absence of specific DNA, the basic region of C/EBP bZip fragment is flexible and partially disordered; binding to a specific DNA recognition sequence induces a fully alpha-helical conformation in the basic region ('induced helical fork model'). This was demonstrated for the intact bZip protein of C/EBP.\",\n      \"method\": \"Circular dichroism (CD) spectroscopy, DNA-binding titration with symmetric and asymmetric enhancers\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct biophysical measurement of conformational change, single lab but rigorous in vitro reconstitution with intact protein and bZip fragment\",\n      \"pmids\": [\"1892816\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Homozygous deletion of c/ebp alpha in mice results in failure to store hepatic glycogen, hypoglycemia, and neonatal death. Mutant livers show 50-70% reduced glycogen synthase mRNA and delayed transcriptional induction of gluconeogenic enzymes PEPCK and glucose-6-phosphatase. Hepatocytes and adipocytes fail to accumulate lipid, and uncoupling protein expression is reduced in brown adipose tissue, establishing C/EBPα as critical for energy homeostasis.\",\n      \"method\": \"Targeted gene knockout (homozygous null mice), Northern blotting, histology\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean germline KO with specific metabolic phenotypes, replicated in subsequent conditional KO studies\",\n      \"pmids\": [\"7652557\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"C/EBPα, c-Myb, and PU.1 cooperatively activate the neutrophil elastase (NE) promoter through their respective binding sites at -57, -49, and -82. Cooperative activation was observed with any combination of these factors. Either of C/EBPα's two transactivation domains cooperated with c-Myb, suggesting a coactivator protein bridges their interaction rather than direct protein-protein contact. Spatial separation of binding sites did not abolish cooperativity.\",\n      \"method\": \"Transient transfection/reporter assay (NIH 3T3, CV-1, 32D cl3 cells), gel shift/EMSA, site-directed mutagenesis of binding sites\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (reporter assay with mutagenesis, EMSA), tested in multiple cell lines, domain mapping\",\n      \"pmids\": [\"8756629\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Conditional deletion of c/ebp alpha specifically in adult mouse liver (via Cre/loxP) reduced expression of bilirubin UDP-glucuronosyltransferase, causing severe jaundice due to increased unconjugated bilirubin. Expression of PEPCK, glycogen synthase, and factor IX was strongly reduced, while transferrin, apoB, and IGF-I were unaffected, establishing C/EBPα as an essential transcriptional regulator of specific metabolic genes in adult liver.\",\n      \"method\": \"Conditional knockout (Cre/loxP recombination via adenoviral Cre delivery), Northern blotting, biochemical phenotyping\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean conditional KO with gene-specific readouts, distinct from the lethal germline KO, multiple target genes examined\",\n      \"pmids\": [\"9315660\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"C/EBP alpha and C/EBP beta can induce eosinophil lineage commitment in multipotent hematopoietic progenitors (MEPs). Eosinophil differentiation can be separated into lineage commitment (transactivation-independent C/EBP function) and maturation (transactivation-dependent). Transactivation-deficient C/EBPβ alleles allowed commitment but blocked maturation.\",\n      \"method\": \"Retroviral forced expression of C/EBP isoforms in MEPs, dominant-negative allele analysis, conditional C/EBPβ activation\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — gain-of-function and dominant-negative loss-of-function with specific phenotypic readouts, domain-function dissection\",\n      \"pmids\": [\"9694805\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Retinoblastoma protein (RB) forms stable complexes with C/EBPα, C/EBPβ, and C/EBPδ. The RB small pocket domain (aa 379-792) is necessary and sufficient for interaction with C/EBP proteins. RB-C/EBP complexes directly bind C/EBP sites on DNA and activate C/EBP-dependent transcription of the surfactant protein D (SP-D) gene promoter.\",\n      \"method\": \"Co-immunoprecipitation, GST pulldown, EMSA, reporter/transient transfection assay, RB domain mutagenesis\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal binding assays and reporter assay with domain mapping, single lab\",\n      \"pmids\": [\"11596110\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"C/EBPβ function is required for mitotic clonal expansion (MCE) during adipogenesis. A dominant-negative C/EBP (A-C/EBP) inhibited turnover of p27/Kip1, expression of cyclin A and CDK2, DNA replication, MCE, and subsequent adipogenesis. Mechanistically, A-C/EBP prevented nuclear import of C/EBPβ by obscuring its nuclear localization signal, blocking its normal punctate centromeric staining.\",\n      \"method\": \"Adenoviral A-C/EBP expression, immunofluorescence, BrdU/DNA replication assay, Western blotting\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — dominant-negative strategy with multiple orthogonal readouts, mechanistic localization finding linked to functional outcome\",\n      \"pmids\": [\"14688407\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"FLT3-activating mutations in AML inhibit C/EBPα function via ERK1/2-mediated phosphorylation of serine 21. Pharmacological inhibition of FLT3 or MEK1 restores granulocytic differentiation. Expression of phosphorylation-resistant C/EBPα (S21A) restores differentiation, whereas the phosphomimetic S21D mutant does not, establishing ERK1/2-mediated S21 phosphorylation as a functional inactivation mechanism.\",\n      \"method\": \"Site-directed mutagenesis (S21A, S21D), stable expression in MV4;11 cells, FLT3/MEK inhibitor treatment, differentiation assay\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis of specific phosphorylation site with gain-of-function and phosphomimetic loss-of-function, mechanistic pathway defined\",\n      \"pmids\": [\"16446383\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Sumoylation of C/EBPα at lysine 159 (K159) prevents association of the SWI/SNF chromatin remodeling complex with C/EBPα, thereby hampering transactivation. K159 lies within the growth inhibitory region of C/EBPα.\",\n      \"method\": \"SUMO modification assay, Co-immunoprecipitation of SWI/SNF with C/EBPα mutants (review citing primary experimental data)\",\n      \"journal\": \"Blood cells, molecules & diseases\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — single review citing primary experimental work; mechanistic claim is well-defined (K159 sumoylation blocks SWI/SNF association) but supporting experiments cited rather than fully described in this abstract\",\n      \"pmids\": [\"18406180\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Genome-wide ChIP analysis in 3T3-L1 adipocytes showed that C/EBPα co-localizes at 3350 of 5299 PPARγ-binding sites. Most genes induced in adipogenesis are bound by both PPARγ and C/EBPα, while very few are PPARγ-specific. C/EBPα and C/EBPβ are both required with PPARγ for robust adipocyte-specific gene expression, demonstrating cooperative orchestration of adipocyte biology through adjacent binding on a genome-wide scale.\",\n      \"method\": \"Chromatin immunoprecipitation coupled with whole-genome tiling arrays (ChIP-chip), bioinformatics motif analysis\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide ChIP in physiologically relevant adipocyte model, multiple ChIP targets validated, loss-of-function for both C/EBPα and C/EBPβ\",\n      \"pmids\": [\"18981473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PU.1 and C/EBPα synergistically create monocyte-specific enhancers that direct NF-κB p65 to distinct genome locations upon TNF-α stimulation. Co-expression of PU.1 and C/EBPα in HeLa cells conferred TNF-α responsiveness to a subset of THP-1-specific NF-κB target genes, establishing C/EBPα as a determinant of cell-type-specific enhancer formation and NF-κB targeting.\",\n      \"method\": \"Genome-wide ChIP-seq, histone modification profiling, transient expression of PU.1 and C/EBPα in HeLa cells, NF-κB reporter assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide location analysis combined with gain-of-function in non-myeloid cells, multiple orthogonal methods\",\n      \"pmids\": [\"21402921\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"C/EBPα controls acquisition and maintenance of adult haematopoietic stem cell (HSC) quiescence. Inducible knockout of C/EBPα in adult HSCs caused pronounced increase in HSC number and enhanced proliferation, resembling fetal liver HSCs. N-Myc was identified as a direct downstream target: loss of C/EBPα caused de-repression of N-Myc, mechanistically linking C/EBPα to HSC cell-cycle control.\",\n      \"method\": \"Inducible Cre-mediated conditional knockout, transcription profiling, ChIP/target gene validation\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — inducible KO with quantitative phenotypic readouts, downstream target identified with mechanistic follow-up\",\n      \"pmids\": [\"23502316\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"A single enhancer located +42 kb from CEBPA is active exclusively in myeloid cells and physically engages the CEBPA promoter. Germline deletion of this enhancer in mice specifically reduced Cebpa levels in HSCs and myeloid-primed progenitors, causing severe granulocytic differentiation defects and loss of HSC maintenance without affecting Cebpa expression in other tissues.\",\n      \"method\": \"CRISPR/Cas9 genome editing, chromosome conformation capture (3C/4C), ChIP, in vivo mouse modeling\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — CRISPR deletion in vivo with defined enhancer-promoter looping, tissue-specific rescue experiment, multiple orthogonal methods\",\n      \"pmids\": [\"26966090\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"R-2-hydroxyglutarate (R-2HG) inhibits FTO (fat mass and obesity-associated protein) activity, leading to increased global m6A RNA modification, which in turn decreases the stability of CEBPA (and MYC) transcripts, suppressing relevant pathways. This established CEBPA mRNA stability as a node regulated by the FTO/m6A axis.\",\n      \"method\": \"FTO enzymatic inhibition assay, m6A-seq, mRNA stability assay, ectopic expression, in vitro and in vivo leukemia models\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — enzymatic inhibition assay with mechanistic follow-up (m6A-seq, mRNA stability), multiple orthogonal methods, replicated in vivo\",\n      \"pmids\": [\"29249359\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Oncogenic C/EBPα p30 isoform (from N-terminal AML mutations) physically interacts with the MLL1 histone methyltransferase complex and shows global co-localization on chromatin. CRISPR/Cas9 mutagenesis of MLL1 induces proliferation arrest and myeloid differentiation in p30-expressing cells. GATA2 was identified as a direct critical transcriptional target of the p30-MLL1 interaction.\",\n      \"method\": \"Co-immunoprecipitation, ChIP-seq, CRISPR/Cas9 MLL1 mutagenesis, pharmacological MLL1 inhibition, gene expression profiling\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, genome-wide co-localization, genetic and pharmacological perturbation with specific phenotypic readouts, target gene identified\",\n      \"pmids\": [\"30679799\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Mutant CEBPA-p30 isoform activates aberrant enhancers not occupied by wild-type C/EBPα, including a leukemic enhancer upstream of Nt5e (CD73) that is physically and functionally linked to that gene. CD73 expression sustained leukemic growth via the CD73/A2AR axis, establishing a direct mechanistic link between a C/EBPα driver mutation and a druggable downstream target.\",\n      \"method\": \"Microscale in vivo ChIP-seq, chromatin conformation capture, comparative gene expression (human AML and mouse Cebpa-Lp30 model), reporter assay, pharmacological targeting\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP-seq with chromatin looping, cross-species validation, functional pharmacological rescue in vivo\",\n      \"pmids\": [\"31309149\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"JAM-A promotes C/EBPα expression through suppression of β-catenin transcriptional activity and through activation of EPAC. C/EBPα then directly binds the promoter of claudin-5 to promote its transcription, enhancing endothelial barrier function. Genetic deletion of JAM-A reduced vascular permeability and claudin-5 levels; C/EBPα gain-of-function increased claudin-5 and decreased permeability; C/EBPα loss-of-function had the opposite effects.\",\n      \"method\": \"Genetic KO (JAM-A mice), ChIP on C/EBPα at claudin-5 promoter, gain/loss-of-function transfection, FITC-dextran permeability assay, pharmacological EPAC activation\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal gain/loss-of-function experiments, ChIP at target promoter, in vivo genetic model with functional permeability readout\",\n      \"pmids\": [\"32673519\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Chronic IL-1β exposure engendered potent selective expansion of Cebpa-knockout HSPCs in competitive settings. Cebpa loss did not confer cell-intrinsic competitive advantage under basal conditions. Mechanistically, C/EBPα mediates IL-1β-driven myeloid differentiation and repression of stem cell gene programs; Cebpa-KO HSPCs are resistant to the pro-differentiative effects of IL-1β, explaining their selective expansion.\",\n      \"method\": \"Competitive transplantation, inducible conditional knockout, gene expression profiling, ectopic CEBPA expression in human AML cells\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — competitive transplantation with inducible KO, mechanistic pathway delineated, human AML validation\",\n      \"pmids\": [\"33914855\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CEBPA directly interacts with the long isoform DNMT3A (but not DNMT3A2). By interacting with the DNMT3A N-terminus, CEBPA blocks DNMT3A from accessing DNA substrate and thereby inhibits its methyltransferase activity. Recurrent AML-associated CEBPA mutation N321D disrupts DNMT3A association and causes aberrant DNA hypermethylation of PRC2 target genes.\",\n      \"method\": \"Co-immunoprecipitation (CEBPA with DNMT3A isoforms), in vitro DNA methyltransferase activity assay, bisulfite sequencing/methylation profiling, site-directed mutagenesis (N321D)\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro enzymatic inhibition assay combined with Co-IP, domain-specific interaction (N-terminus), mutagenesis of AML-relevant site with methylome profiling\",\n      \"pmids\": [\"35080973\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CEBPA drives extensive chromatin compartment switching and formation of long-range chromatin hubs during B cell-to-macrophage transdifferentiation. The intrinsically disordered region (IDR) of CEBPA undergoes phase separation in vitro dependent on aromatic residues, and CEBPA forms nuclear foci in vivo in multiple cell types. This suggests phase separation through the IDR underlies CEBPA foci formation and 3D chromatin hub organization.\",\n      \"method\": \"Hi-C/chromatin conformation analysis, in vitro phase separation assay with purified CEBPA IDR, mutagenesis of aromatic residues, live-cell imaging of nuclear foci, ChIP-seq\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro phase separation with mutagenesis, supported by genome-wide chromatin architecture data and live imaging, multiple orthogonal methods in single study\",\n      \"pmids\": [\"37516962\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CEBPA restricts alveolar type 2 (AT2) cell plasticity in the mouse lung. Without CEBPA, neonatal AT2 cells reactivate the SOX9 progenitor program (mature AT2 cells cannot). Sendai virus infection bestows mature AT2 cells with neonatal plasticity in a Cebpa-mutant-dependent manner. Mechanistically, CEBPA promotes the AT2 program by recruiting the lineage TF NKX2-1.\",\n      \"method\": \"Conditional knockout (neonatal and adult), viral infection model, scRNA-seq/transcriptome profiling, ChIP/co-factor recruitment assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO at different developmental stages, mechanistic co-factor recruitment (NKX2-1), epigenetic maturation profiling, multiple orthogonal readouts\",\n      \"pmids\": [\"38755149\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CEBPβ preferentially binds T:G mismatches (product of 5mC deamination) with >60-fold increased affinity relative to normal C:G base pairs within a CEBP binding site. This enhanced mismatch binding inhibits repair by TDG and MBD4 in vitro, as well as repair of U:G mismatches, providing a mechanism by which CEBP site occupancy drives C-to-T somatic mutations.\",\n      \"method\": \"In vitro binding affinity assay (fluorescence anisotropy/EMSAs), in vitro DNA glycosylase repair inhibition assay, somatic mutation enrichment analysis\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — quantitative in vitro binding and enzymatic repair inhibition assays, mechanistically defined, single lab but multiple orthogonal biochemical methods\",\n      \"pmids\": [\"33877329\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The p53-KLF4-CEBPA axis is functionally connected: CEBPA gene transcription can be directly activated by p53 and KLF4. In AML patient cells, p53 inactivation correlates with reduced KLF4 and CEBPA protein levels. Restoring p53 function with chemotherapy or non-genotoxic p53 activators induces CEBPA gene expression and myeloid differentiation in AML cell lines.\",\n      \"method\": \"Reporter assay (CEBPA promoter with p53/KLF4 co-expression), protein level analysis in patient samples, pharmacological p53 restoration\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — reporter assay demonstrates direct p53/KLF4 activation of CEBPA promoter, but mechanistic depth is limited to co-transfection; patient correlation data is associative\",\n      \"pmids\": [\"26408402\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CEBPA encodes a bZIP transcription factor that binds CCAAT/enhancer elements (with DNA-induced helix formation in its basic region), forms homo- and heterodimers with other C/EBP family members, and cooperates with PU.1, c-Myb, PPARγ, and RB to activate myeloid- and adipocyte-specific gene programs; its activity is regulated post-translationally by ERK1/2-mediated phosphorylation at S21 (blocking differentiation), sumoylation at K159 (blocking SWI/SNF recruitment), and interaction with DNMT3A (inhibiting de novo DNA methylation), while its IDR mediates phase separation and 3D chromatin hub formation; in hematopoiesis it maintains adult HSC quiescence by repressing N-Myc, drives granulocytic differentiation via a myeloid-specific +42 kb enhancer, and oncogenic N-terminal truncation mutations produce a p30 isoform that aberrantly co-opts the MLL1 complex to activate CD73 and GATA2 and disrupt DNMT3A interaction, causing hypermethylation and leukemogenesis.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CEBPA encodes a basic-region leucine-zipper (bZIP) transcription factor that binds CCAAT/enhancer DNA elements and orchestrates lineage-specific gene programs across metabolism, hematopoiesis, and epithelial differentiation [#0, #2]. Its DNA-binding domain adopts an 'induced helical fork' conformation, becoming fully alpha-helical only upon engaging a specific recognition sequence [#2]. C/EBPalpha functions combinatorially: it homo- and heterodimerizes with other C/EBP family members [#1], cooperates with c-Myb and PU.1 to build myeloid enhancers and with PU.1 to specify cell-type-restricted NF-kappaB targeting [#4, #12], partners with PPARgamma at thousands of shared sites to drive adipogenesis [#11], and recruits lineage factors such as NKX2-1 to enforce alveolar type 2 identity [#22]. In liver it is essential for energy homeostasis, controlling glycogen storage, gluconeogenic enzymes, and bilirubin conjugation [#3, #5]. In hematopoiesis it maintains adult HSC quiescence by repressing N-Myc and mediates IL-1beta-driven myeloid differentiation, such that its loss confers selective expansion under inflammatory stress; a myeloid-specific +42 kb enhancer that loops to the CEBPA promoter restricts this activity to the myeloid compartment [#13, #14, #19]. C/EBPalpha activity is tuned post-translationally—ERK1/2 phosphorylation at serine 21 inactivates it downstream of oncogenic FLT3 and blocks granulocytic differentiation, while sumoylation at K159 blocks SWI/SNF recruitment [#9, #10]—and its intrinsically disordered region drives aromatic-residue-dependent phase separation that organizes long-range chromatin hubs [#21]. C/EBPalpha also directly binds the long DNMT3A isoform and inhibits its methyltransferase activity, coupling the factor to genome methylation control [#20]. Recurrent AML mutations corrupt these functions: the N-terminally truncated p30 isoform co-opts the MLL1 complex to activate aberrant enhancers and targets including GATA2 and CD73, while the N321D mutation disrupts the DNMT3A interaction to cause hypermethylation of PRC2 targets [#16, #17, #20].\",\n  \"teleology\": [\n    {\n      \"year\": 1988,\n      \"claim\": \"Establishing that CEBPA encodes a single sequence-specific DNA-binding protein defined the molecular identity of the factor and localized its activity to a discrete domain.\",\n      \"evidence\": \"recombinant bacterial expression with in vitro DNA-binding and protease fragment mapping\",\n      \"pmids\": [\"2850264\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structure of the DNA-bound complex\", \"Cellular partners and target genes not yet defined\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Biophysical characterization showed the basic region is disordered until DNA binding induces a fully helical fork, explaining how specific recognition is achieved.\",\n      \"evidence\": \"circular dichroism and DNA-binding titration on intact bZip protein\",\n      \"pmids\": [\"1892816\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Single biophysical method\", \"Does not address dimer selectivity or partner-dependent binding in vivo\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Temporal expression and heterodimerization data placed C/EBPalpha as a terminal effector in a differentiation cascade rather than an early inducer.\",\n      \"evidence\": \"Western/Northern blotting, heterodimerization and transactivation assays in adipocyte and hepatoma cells\",\n      \"pmids\": [\"1840554\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of cascade hand-off between C/EBP family members unresolved\", \"In vivo physiological roles not yet tested\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Germline knockout established C/EBPalpha as essential for energy homeostasis, linking the transcription factor to specific metabolic gene programs in liver and fat.\",\n      \"evidence\": \"homozygous null mice with Northern and histological phenotyping\",\n      \"pmids\": [\"7652557\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Neonatal lethality precludes adult analysis\", \"Direct vs indirect target genes not separated\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Adult liver-specific conditional deletion separated developmental requirement from ongoing transcriptional control, identifying discrete target genes regulated in mature hepatocytes.\",\n      \"evidence\": \"Cre/loxP conditional KO with Northern and biochemical phenotyping\",\n      \"pmids\": [\"9315660\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of target-gene selectivity unknown\", \"Cofactor requirements not defined\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Demonstrating cooperative activation with c-Myb and PU.1 revealed C/EBPalpha works combinatorially at myeloid promoters, likely via a bridging coactivator.\",\n      \"evidence\": \"reporter assays with binding-site mutagenesis and EMSA across multiple cell lines\",\n      \"pmids\": [\"8756629\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the bridging coactivator not established\", \"Direct vs indirect cooperativity not resolved\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Separating lineage commitment (transactivation-independent) from maturation (transactivation-dependent) showed C/EBP function is modular in hematopoietic fate decisions.\",\n      \"evidence\": \"retroviral forced expression and dominant-negative alleles in multipotent progenitors\",\n      \"pmids\": [\"9694805\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transactivation-independent commitment mechanism undefined\", \"Overlap with C/EBPbeta function not fully separated\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identifying RB as a direct binding partner that activates C/EBP-dependent transcription linked C/EBP factors to a cell-cycle regulator at target promoters.\",\n      \"evidence\": \"reciprocal Co-IP, GST pulldown, EMSA and reporter assays with RB domain mapping\",\n      \"pmids\": [\"11596110\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Physiological relevance in vivo not established\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Pinpointing ERK1/2 phosphorylation of serine 21 as a functional off-switch explained how oncogenic FLT3 signaling blocks granulocytic differentiation.\",\n      \"evidence\": \"S21A/S21D mutagenesis with stable expression and kinase-inhibitor differentiation assays in AML cells\",\n      \"pmids\": [\"16446383\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural consequence of S21 phosphorylation unknown\", \"Whether phosphorylation alters DNA binding vs cofactor recruitment unresolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Sumoylation at K159 was identified as a modification that blocks SWI/SNF recruitment, defining a chromatin-remodeling control point on C/EBPalpha.\",\n      \"evidence\": \"SUMO modification and Co-IP of SWI/SNF with C/EBPalpha mutants (review citing primary data)\",\n      \"pmids\": [\"18406180\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Primary experiments cited rather than fully described\", \"SUMO E3 ligase and dynamics not defined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Genome-wide co-localization with PPARgamma established that C/EBPalpha cooperatively orchestrates the adipocyte gene program through adjacent binding.\",\n      \"evidence\": \"ChIP-chip in 3T3-L1 adipocytes with motif analysis and loss-of-function\",\n      \"pmids\": [\"18981473\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Order of recruitment between PPARgamma and C/EBPalpha not resolved\", \"Direct physical interaction at shared sites not shown\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"PU.1/C/EBPalpha synergy in creating monocyte-specific enhancers showed C/EBPalpha determines cell-type-specific NF-kappaB genomic targeting.\",\n      \"evidence\": \"ChIP-seq, histone profiling and ectopic PU.1/C/EBPalpha expression in non-myeloid cells\",\n      \"pmids\": [\"21402921\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of de novo enhancer establishment not detailed\", \"Direct C/EBPalpha-PU.1 contact not demonstrated\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Inducible HSC knockout identified C/EBPalpha as a controller of adult HSC quiescence acting through direct repression of N-Myc.\",\n      \"evidence\": \"inducible conditional KO with transcriptional profiling and ChIP target validation\",\n      \"pmids\": [\"23502316\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How C/EBPalpha represses N-Myc mechanistically not defined\", \"Cofactors of repression unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Positioning CEBPA downstream of a p53-KLF4 axis provided a transcriptional input controlling its expression and a route to restore differentiation in AML.\",\n      \"evidence\": \"CEBPA-promoter reporter assays with p53/KLF4, patient-sample correlation, pharmacological p53 restoration\",\n      \"pmids\": [\"26408402\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Promoter activation shown only by co-transfection\", \"Patient correlation is associative\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"A myeloid-specific +42 kb enhancer that loops to the promoter was shown to confer tissue-restricted CEBPA expression essential for granulopoiesis and HSC maintenance.\",\n      \"evidence\": \"in vivo CRISPR enhancer deletion with 3C/4C, ChIP and phenotyping\",\n      \"pmids\": [\"26966090\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Trans-factors binding the enhancer not fully cataloged\", \"Mechanism of looping not defined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identifying CEBPA mRNA as a target of the FTO/m6A axis revealed post-transcriptional control of its abundance in leukemia.\",\n      \"evidence\": \"FTO inhibition assay, m6A-seq, mRNA stability assays in leukemia models\",\n      \"pmids\": [\"29249359\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"m6A reader mediating CEBPA decay not identified here\", \"Site-specific m6A marks on CEBPA not mapped\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"The oncogenic p30 isoform was shown to physically co-opt the MLL1 complex to activate aberrant targets such as GATA2, defining a gain-of-function leukemogenic mechanism.\",\n      \"evidence\": \"reciprocal Co-IP, ChIP-seq, CRISPR and pharmacological MLL1 perturbation\",\n      \"pmids\": [\"30679799\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of p30-MLL1 interaction unknown\", \"Why full-length C/EBPalpha does not recruit MLL1 not resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Mapping p30-specific aberrant enhancers to CD73 connected a CEBPA driver mutation to a druggable downstream adenosine axis.\",\n      \"evidence\": \"in vivo ChIP-seq, chromatin conformation capture, cross-species expression and pharmacological targeting\",\n      \"pmids\": [\"31309149\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants of p30 enhancer selectivity not defined\", \"Generality across CEBPA-mutant AML subtypes unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Competitive transplantation revealed C/EBPalpha as the effector of IL-1beta-driven myeloid differentiation, explaining selective expansion of Cebpa-mutant clones under chronic inflammation.\",\n      \"evidence\": \"inducible conditional KO with competitive transplantation, profiling and human AML validation\",\n      \"pmids\": [\"33914855\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct IL-1beta-to-CEBPA signaling intermediates not mapped\", \"Whether effect is shared with other inflammatory cytokines untested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrating high-affinity binding of CEBP sites to T:G mismatches that blocks glycosylase repair provided a mechanism linking factor occupancy to somatic C-to-T mutation.\",\n      \"evidence\": \"in vitro binding affinity and glycosylase repair-inhibition assays with somatic mutation enrichment analysis\",\n      \"pmids\": [\"33877329\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Shown for CEBPbeta; CEBPA-specific contribution not isolated\", \"In vivo mutagenesis at CEBPA-bound sites not demonstrated\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Placing C/EBPalpha downstream of JAM-A signaling and upstream of claudin-5 transcription extended its role to endothelial barrier function.\",\n      \"evidence\": \"JAM-A KO mice, ChIP at claudin-5 promoter, reciprocal gain/loss-of-function and permeability assays\",\n      \"pmids\": [\"32673519\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How JAM-A/EPAC signaling reaches CEBPA not detailed\", \"Cofactors at the claudin-5 promoter unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Direct inhibition of DNMT3A methyltransferase activity by CEBPA, disrupted by the AML N321D mutation, established CEBPA as a guardian against aberrant DNA methylation.\",\n      \"evidence\": \"Co-IP with DNMT3A isoforms, in vitro methyltransferase assay, bisulfite profiling and N321D mutagenesis\",\n      \"pmids\": [\"35080973\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of CEBPA-DNMT3A N-terminus contact unknown\", \"Genomic targeting of the inhibitory effect not fully resolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showing that the CEBPA IDR phase-separates and organizes long-range chromatin hubs added a biophysical layer to how the factor reshapes 3D genome architecture.\",\n      \"evidence\": \"in vitro phase separation with aromatic-residue mutagenesis, Hi-C, live imaging and ChIP-seq during transdifferentiation\",\n      \"pmids\": [\"37516962\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional requirement of phase separation for target activation not isolated\", \"Whether condensates form at endogenous physiological concentrations unresolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Conditional deletion in lung showed CEBPA restricts alveolar type 2 cell plasticity by recruiting NKX2-1 and suppressing a SOX9 progenitor program.\",\n      \"evidence\": \"neonatal and adult conditional KO, viral infection model, scRNA-seq and cofactor recruitment assays\",\n      \"pmids\": [\"38755149\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of NKX2-1 recruitment not detailed\", \"How injury overrides CEBPA restriction unresolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the combinatorial logic—dimer partner choice, IDR-driven condensates, post-translational marks, and DNMT3A control—is integrated to select context-specific target genes remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No unified structural model of partner-dependent target selection\", \"Relationship between phase separation and post-translational modification states untested\", \"Quantitative link between condensate formation and transcriptional output missing\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1, 4, 11, 13, 18]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 2, 23]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [20]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [8, 21]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [21]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 1, 4, 11]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [6, 13, 14, 22]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [3, 5, 11]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [16, 17, 20]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [10, 16, 21]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"PU.1\", \"c-Myb\", \"PPARG\", \"RB1\", \"MLL1\", \"DNMT3A\", \"NKX2-1\", \"CEBPB\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}